Clinical, histological, immunohistochemical and genetic factors associated with measurable response of high-risk canine mast cell tumours to tyrosine kinase inhibitors

Rodrigo dos Santos Horta; Antonio Giuliano; Gleidice Eunice Lavalle; Mariana de Pádua Costa; Roberto Baracat de Araújo; Fernando Constantino-Casas; Jane Margaret Dobson

doi:10.3892/ol.2017.7323

Clinical, histological, immunohistochemical and genetic factors associated with measurable response of high-risk canine mast cell tumours to tyrosine kinase inhibitors

Rodrigo dos Santos Horta^*
, Antonio Giuliano
, Gleidice Eunice Lavalle
, Mariana de Pádua Costa
, Roberto Baracat de Araújo
, Fernando Constantino-Casas
, Jane Margaret Dobson

^*Corresponding author for this work

Research output: Journal Publications and Reviews › RGC 21 - Publication in refereed journal › peer-review

19 Citations (Scopus)

28 Downloads (CityUHK Scholars)

Abstract

The aim of the present prospective-retrospective study was to evaluate the response of high-risk canine mast cell tumours (MCTs) to tyrosine kinase inhibitors (TKIs) and to correlate this with prognostic factors. A total of 24 dogs presented with macroscopic cutaneous MCTs at disease stage II or III, and therefore, at high-risk of associated mortality, were included in the study and treated with masitinib (n=20) or toceranib (n=4). A total of 12/24 dogs achieved an objective response and the overall survival (OS) for all subjects was 113 days. Dogs responding to treatment had a significant increase in OS compared to non-responders (146.5 days vs. 47 days, P=0.02). Internal tandem duplications in exon 11 of the c-kit gene were identified in 6/24 cases. Ki67, KIT immunolabelling and c-kit mutation did not provide information regarding prognosis or prediction of response to TKIs in this population. Initial response to TKIs appears to be the most reliable prognostic factor for survival duration.

Original language	English
Pages (from-to)	129-136
Journal	Oncology Letters
Volume	15
Issue number	1
DOIs	https://doi.org/10.3892/ol.2017.7323
Publication status	Published - 1 Jan 2018
Externally published	Yes

Bibliographical note

Publication details (e.g. title, author(s), publication statuses and dates) are captured on an “AS IS” and “AS AVAILABLE” basis at the time of record harvesting from the data source. Suggestions for further amendments or supplementary information can be sent to [email protected].

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research Keywords

C-kit
Cancer
Dog
Masitinib
Prednisolone
Prednisone
Toceranib

Publisher's Copyright Statement

This full text is made available under CC-BY-NC-ND 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/

Access Output

10.3892/ol.2017.7323

86052292.pdfFinal Published version, 0.98 MBLicence: CC BY-NC-ND

Other Access Options

Check CityUHK Library

Permanent Link

Right click to copy link

Cite this

@article{2aa65076e39742a49642e53258039c65,

title = "Clinical, histological, immunohistochemical and genetic factors associated with measurable response of high-risk canine mast cell tumours to tyrosine kinase inhibitors",

abstract = "The aim of the present prospective-retrospective study was to evaluate the response of high-risk canine mast cell tumours (MCTs) to tyrosine kinase inhibitors (TKIs) and to correlate this with prognostic factors. A total of 24 dogs presented with macroscopic cutaneous MCTs at disease stage II or III, and therefore, at high-risk of associated mortality, were included in the study and treated with masitinib (n=20) or toceranib (n=4). A total of 12/24 dogs achieved an objective response and the overall survival (OS) for all subjects was 113 days. Dogs responding to treatment had a significant increase in OS compared to non-responders (146.5 days vs. 47 days, P=0.02). Internal tandem duplications in exon 11 of the c-kit gene were identified in 6/24 cases. Ki67, KIT immunolabelling and c-kit mutation did not provide information regarding prognosis or prediction of response to TKIs in this population. Initial response to TKIs appears to be the most reliable prognostic factor for survival duration.",

keywords = "C-kit, Cancer, Dog, Masitinib, Prednisolone, Prednisone, Toceranib",

author = "Horta, \{Rodrigo dos Santos\} and Antonio Giuliano and Lavalle, \{Gleidice Eunice\} and Costa, \{Mariana de P{\'a}dua\} and \{de Ara{\'u}jo\}, \{Roberto Baracat\} and Fernando Constantino-Casas and Dobson, \{Jane Margaret\}",

note = "Publication details (e.g. title, author(s), publication statuses and dates) are captured on an “AS IS” and “AS AVAILABLE” basis at the time of record harvesting from the data source. Suggestions for further amendments or supplementary information can be sent to [email protected]. ",

year = "2018",

month = jan,

day = "1",

doi = "10.3892/ol.2017.7323",

language = "English",

volume = "15",

pages = "129--136",

journal = "Oncology Letters",

issn = "1792-1074",

publisher = "Spandidos Publications",

number = "1",

}

Clinical, histological, immunohistochemical and genetic factors associated with measurable response of high-risk canine mast cell tumours to tyrosine kinase inhibitors. / Horta, Rodrigo dos Santos; Giuliano, Antonio; Lavalle, Gleidice Eunice et al.
In: Oncology Letters, Vol. 15, No. 1, 01.01.2018, p. 129-136.

Research output: Journal Publications and Reviews › RGC 21 - Publication in refereed journal › peer-review

TY - JOUR

T1 - Clinical, histological, immunohistochemical and genetic factors associated with measurable response of high-risk canine mast cell tumours to tyrosine kinase inhibitors

AU - Horta, Rodrigo dos Santos

AU - Giuliano, Antonio

AU - Lavalle, Gleidice Eunice

AU - Costa, Mariana de Pádua

AU - de Araújo, Roberto Baracat

AU - Constantino-Casas, Fernando

AU - Dobson, Jane Margaret

N1 - Publication details (e.g. title, author(s), publication statuses and dates) are captured on an “AS IS” and “AS AVAILABLE” basis at the time of record harvesting from the data source. Suggestions for further amendments or supplementary information can be sent to [email protected].

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The aim of the present prospective-retrospective study was to evaluate the response of high-risk canine mast cell tumours (MCTs) to tyrosine kinase inhibitors (TKIs) and to correlate this with prognostic factors. A total of 24 dogs presented with macroscopic cutaneous MCTs at disease stage II or III, and therefore, at high-risk of associated mortality, were included in the study and treated with masitinib (n=20) or toceranib (n=4). A total of 12/24 dogs achieved an objective response and the overall survival (OS) for all subjects was 113 days. Dogs responding to treatment had a significant increase in OS compared to non-responders (146.5 days vs. 47 days, P=0.02). Internal tandem duplications in exon 11 of the c-kit gene were identified in 6/24 cases. Ki67, KIT immunolabelling and c-kit mutation did not provide information regarding prognosis or prediction of response to TKIs in this population. Initial response to TKIs appears to be the most reliable prognostic factor for survival duration.

AB - The aim of the present prospective-retrospective study was to evaluate the response of high-risk canine mast cell tumours (MCTs) to tyrosine kinase inhibitors (TKIs) and to correlate this with prognostic factors. A total of 24 dogs presented with macroscopic cutaneous MCTs at disease stage II or III, and therefore, at high-risk of associated mortality, were included in the study and treated with masitinib (n=20) or toceranib (n=4). A total of 12/24 dogs achieved an objective response and the overall survival (OS) for all subjects was 113 days. Dogs responding to treatment had a significant increase in OS compared to non-responders (146.5 days vs. 47 days, P=0.02). Internal tandem duplications in exon 11 of the c-kit gene were identified in 6/24 cases. Ki67, KIT immunolabelling and c-kit mutation did not provide information regarding prognosis or prediction of response to TKIs in this population. Initial response to TKIs appears to be the most reliable prognostic factor for survival duration.

KW - C-kit

KW - Cancer

KW - Dog

KW - Masitinib

KW - Prednisolone

KW - Prednisone

KW - Toceranib

UR - https://www.scopus.com/pages/publications/85035327629

UR - https://www.scopus.com/record/pubmetrics.uri?eid=2-s2.0-85035327629&origin=recordpage

U2 - 10.3892/ol.2017.7323

DO - 10.3892/ol.2017.7323

M3 - RGC 21 - Publication in refereed journal

C2 - 29387214

SN - 1792-1074

VL - 15

SP - 129

EP - 136

JO - Oncology Letters

JF - Oncology Letters

IS - 1

ER -

Clinical, histological, immunohistochemical and genetic factors associated with measurable response of high-risk canine mast cell tumours to tyrosine kinase inhibitors

Abstract

Bibliographical note

UN SDGs

Research Keywords

Publisher's Copyright Statement

Access Output

Other Access Options

Permanent Link

Other Files and Links

Fingerprint

Cite this